At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 308 enrolled
Drug / intervention
Canagliflozin +1 moredrug
Likely dose
Canagliflozin 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
In Brief
A Phase 3 clinical trial evaluating Canagliflozin and Placebo for Diabetic Nephropathy. Completed, enrolled 308 participants across 26 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Nephropathy
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedFeb 2018
Primary CompletionJan 2021
TodayJul 2026
First PostedFeb 19, 2018
Enrollment StartFeb 15, 2018
Primary CompletionJan 21, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.4 years ago
Interventions
Canagliflozindrug
Canagliflozin 100mg orally once daily
Placebodrug
Placebo orally once daily